Login / Signup

Using the K/BxN mouse model of endogenous, chronic, rheumatoid arthritis for the evaluation of potential immunoglobulin-based therapeutic agents, including IVIg and Fc-μTP-L309C, a recombinant IgG1 Fc hexamer.

Bonnie J B LewisJade VilleMegan BlacquiereSelena CenRolf SpirigAdrian W ZuercherFabian KäsermannDonald R Branch
Published in: BMC immunology (2019)
Our results show that Fc-μTP-L309C is a powerful treatment for the prevention and amelioration of severe, chronic arthritis in a true autoimmune mouse model of RA. Thus, the K/BxN endogenous arthritis model should be useful for testing potential therapeutics for RA. Our findings provide rationale for further examination of the treatment efficacy of immunoglobulin-based therapeutics in rheumatoid arthritis.
Keyphrases
  • rheumatoid arthritis
  • mouse model
  • disease activity
  • ankylosing spondylitis
  • interstitial lung disease
  • small molecule
  • multiple sclerosis
  • drug induced
  • clinical trial
  • systemic lupus erythematosus
  • combination therapy